Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.36M | 28.43M | 42.47M | 27.26M | 25.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.36M | 28.43M | 42.47M | 27.26M | 25.60M |
| Cost of Revenue | 5.00M | 1.35M | 2.10M | 1.38M | 1.35M |
| Gross Profit | 47.36M | 27.08M | 40.37M | 25.88M | 24.25M |
| SG&A Expenses | 39.27M | 32.92M | 27.57M | 23.99M | 25.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -252.20K | -719.90K | 487.40K | 15.50K | -2.59M |
| Total Operating Expenses | 55.31M | 48.04M | 40.19M | 42.03M | 32.74M |
| Operating Income | -2.95M | -19.61M | 2.28M | -14.77M | -7.14M |
| Income Before Tax | -3.99M | -23.79M | -1.34M | -15.19M | -6.71M |
| Income Tax Expenses | 450.60K | -112.00K | 386.70K | 395.70K | 2.02M |
| Earnings from Continuing Operations | -4.44M | -23.68M | -1.73M | -15.58M | -8.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.44M | -23.68M | -1.73M | -15.58M | -8.74M |
| EBIT | -2.95M | -19.61M | 2.28M | -14.77M | -7.14M |
| EBITDA | -2.85M | -19.51M | 2.38M | -14.72M | -7.09M |
| EPS Basic | -0.08 | -0.44 | -0.03 | -0.29 | -0.16 |
| Normalized Basic EPS | -0.05 | -0.28 | -0.02 | -0.18 | -0.08 |
| EPS Diluted | -0.08 | -0.44 | -0.03 | -0.29 | -0.16 |
| Normalized Diluted EPS | -0.05 | -0.28 | -0.02 | -0.18 | -0.08 |
| Average Basic Shares Outstanding | 53.69M | 53.67M | 53.67M | 53.67M | 53.67M |
| Average Diluted Shares Outstanding | 53.69M | 53.67M | 53.67M | 53.67M | 53.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
